Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of alemtuzumab in relapsing-remitting multiple sclerosis
NL-OMON42054Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of alemtuzumab in multiple sclerosis (MS), sponsored by Sanofi. Primary endpoint: Long-term safety of alemtuzumab. Started Mar 2015; status: active, not recruiting.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON42054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42054.